Advertisement
MRVI vs TLSA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRVI is a Hold and TLSA is a Hold.
Aroon Indicator for MRVI shows an upward move is likely
MRVI's Aroon Indicator triggered a bullish signal on October 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In 158 of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +8.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 205 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
MRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for MRVI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MRVI moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRVI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.148) is normal, around the industry mean (2.973). P/E Ratio (-13.340) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TLSA's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLSA's RSI Indicator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The 10-day moving average for TLSA crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +8.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSA advanced for three days, in 204 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 77 of 100 cases where TLSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSA as a result. In 88 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSA turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
TLSA moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. TLSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.988) is normal, around the industry mean (2.973). P/E Ratio (-5.882) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRVI | TLSA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 35 | 59 | |
P/E GROWTH RATING 1..100 | 42 | 38 | |
SEASONALITY SCORE 1..100 | n/a | 19 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRVI's Valuation (16) in the null industry is significantly better than the same rating for TLSA (85) in the Biotechnology industry. This means that MRVI’s stock grew significantly faster than TLSA’s over the last 12 months.
MRVI's Profit vs Risk Rating (100) in the null industry is in the same range as TLSA (100) in the Biotechnology industry. This means that MRVI’s stock grew similarly to TLSA’s over the last 12 months.
MRVI's SMR Rating (97) in the null industry is in the same range as TLSA (99) in the Biotechnology industry. This means that MRVI’s stock grew similarly to TLSA’s over the last 12 months.
MRVI's Price Growth Rating (35) in the null industry is in the same range as TLSA (59) in the Biotechnology industry. This means that MRVI’s stock grew similarly to TLSA’s over the last 12 months.
TLSA's P/E Growth Rating (38) in the Biotechnology industry is in the same range as MRVI (42) in the null industry. This means that TLSA’s stock grew similarly to MRVI’s over the last 12 months.
| MRVI | TLSA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 4 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 81% |
| Advances ODDS (%) | 2 days ago 79% | 14 days ago 84% |
| Declines ODDS (%) | 10 days ago 83% | 18 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 82% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 77% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRVI’s FA Score shows that 1 FA rating(s) are green while TLSA’s FA Score has 0 green FA rating(s).
- MRVI’s FA Score: 1 green, 4 red.
- TLSA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRVI’s TA Score shows that 3 TA indicator(s) are bullish while TLSA’s TA Score has 5 bullish TA indicator(s).
- MRVI’s TA Score: 3 bullish, 7 bearish.
- TLSA’s TA Score: 5 bullish, 4 bearish.
Price Growth
MRVI (@Biotechnology) experienced а 0.00% price change this week, while TLSA (@Biotechnology) price change was -4.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
MRVI is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MRVI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To MRVI | 1D Price Change % | ||
|---|---|---|---|---|
| MRVI | 100% | -6.61% | ||
| MRNA - MRVI | 46% Loosely correlated | -17.57% | ||
| BNTX - MRVI | 42% Loosely correlated | -1.77% | ||
| RXRX - MRVI | 41% Loosely correlated | -1.65% | ||
| TWST - MRVI | 40% Loosely correlated | -9.16% | ||
| NVAX - MRVI | 39% Loosely correlated | -9.26% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MYHC | 24.45 | 0.03 | +0.10% |
| State Street My2029 High Yield Corporate Bond ETF (MYHC) | |||
| DMAX | 27.87 | -0.04 | -0.14% |
| iShares Large Cap Max Buffer Dec ETF | |||
| POWR | 24.53 | -0.39 | -1.57% |
| iShares U.S. Power Infrastructure ETF (POWR) | |||
| PICK | 55.07 | -2.41 | -4.19% |
| iShares MSCI Global Metals & Mining Producers ETF (PICK) | |||
| WARP | 17.21 | -0.98 | -5.39% |
| VanEck Space ETF (WARP) | |||